期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 177, 期 11, 页码 2413-2433出版社
WILEY
DOI: 10.1111/bph.1500510.1111/bph.15005
关键词
-
资金
- NIDDK [ZIADK31116]
- Independent Research Fund Denmark [DFF-4002-00162]
- State of Saxony, Germany
- Integrated Research and Treatment Center (IFB) AdiposityDiseases (BMBF)
- German Research Foundation [FOR2372, GRK1873, SFB 1052]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK031116] Funding Source: NIH RePORTER
Eight G protein-coupled P2Y receptor subtypes respond to extracellular adenine and uracil mononucleotides and dinucleotides. P2Y receptors belong to the delta group of rhodopsin-like GPCRs and contain two structurally distinct subfamilies: P2Y(1), P2Y(2), P2Y(4), P2Y(6), and P2Y(11) (principally G(q) protein-coupled P2Y(1)-like) and P2Y(12-14) (principally G(i) protein-coupled P2Y(12)-like) receptors. Brain P2Y receptors occur in neurons, glial cells, and vasculature. Endothelial P2Y(1), P2Y(2), P2Y(4), and P2Y(6) receptors induce vasodilation, while smooth muscle P2Y(2), P2Y(4), and P2Y(6) receptor activation leads to vasoconstriction. Pancreatic P2Y(1) and P2Y(6) receptors stimulate while P2Y(13) receptors inhibits insulin secretion. Antagonists of P2Y(12) receptors, and potentially P2Y(1) receptors, are anti-thrombotic agents, and a P2Y(2)/P2Y(4) receptor agonist treats dry eye syndrome in Asia. P2Y receptor agonists are generally pro-inflammatory, and antagonists may eventually treat inflammatory conditions. This article reviews recent developments in P2Y receptor pharmacology (using synthetic agonists and antagonists), structure and biophysical properties (using X-ray crystallography, mutagenesis and modelling), physiological and pathophysiological roles, and present and potentially future therapeutic targeting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据